Antiplatelet Prophylaxis Reduces the Risk of Early Hepatic Artery Thrombosis Following Liver Transplantation in High-Risk Patients
Transplant International · 2024
DOI: 10.3389/ti.2024.13440 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant International, 2024. Verfasst von Iulia Minciuna und 8 weiteren Autor:innen. Beteiligte Einrichtung: Erasmus Medical Center Transplant Institute, Erasmus University Medical Center Rotterdam, Rotterdam, Netherlands. Hauptthemen laut MEDLINE: Liver Transplantation, Hepatic Artery, Thrombosis, Platelet Aggregation Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The prevention of hepatic artery thrombosis (HAT) is pivotal for graft survival immediately after liver transplantation (LT). This study aimed to identify risk factors (RF) for early HAT (eHAT) and assess the benefit of antiplatelet prophylaxis (AP). This retrospective single-center study included 836 adult patients who underwent LT between 2007 and 2022. AP was administered for 3 months in N = 127 patients for surgical reasons. In total, 836 patients underwent LT, of whom 5.5% developed eHAT. In multivariable analysis, arterial anastomotic redo (aHR = 4.33), arterial reconstruction (aHR = 3.72) and cryptogenic liver cirrhosis (aHR = 4.25) were independent RFs for eHAT and AP appeared to be protective (aHR = 0.18). Indeed, in patients with at least one RF who received AP (RF+AP+, n = 94), the eHAT rate was significantly lower (3.2% vs. 21.3%, p < 0.001) than in those with RF who did not receive AP (RF+AP−, n = 89). The effect was even more pronounced when focusing on surgical RF alone (i.e., redo and/or reconstruction) with an additional improvement in 1 year graft survival of 85.3% vs. 70.4%, p = 0.02. AP did not pose an increased risk of bleeding. In conclusion, the main RFs for eHAT include arterial anastomotic redo, arterial reconstruction and cryptogenic liver cirrhosis as LT indications. Our results suggest that AP may protect against eHAT development in these high-risk patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Erasmus Medical Center Transplant Institute, Erasmus University Medical Center Rotterdam, Rotterdam, Netherlands.
- University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania.
- Octavian Fodor Gastroenterology Institute, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
- Department of Surgery, Division of Hepato-Pancreato-Biliary and Transplant Surgery, Erasmus Transplant Institute University Medical Center Rotterdam, Rotterdam, Netherlands.
- Toronto General Hospital, Toronto, ON, Canada.
Zitieren
APA
Minciuna, I., De Jonge, J., Den Hoed, C., Maan, R., Polak, W. G., Porte, R. J., Janssen, H. L. A., Procopet, B., & Darwish Murad, S. (2024). Antiplatelet Prophylaxis Reduces the Risk of Early Hepatic Artery Thrombosis Following Liver Transplantation in High-Risk Patients. Transplant International. https://doi.org/10.3389/ti.2024.13440
Vancouver
Minciuna I, De Jonge J, Den Hoed C, Maan R, Polak WG, Porte RJ, et al. Antiplatelet Prophylaxis Reduces the Risk of Early Hepatic Artery Thrombosis Following Liver Transplantation in High-Risk Patients. Transplant International. 2024. doi:10.3389/ti.2024.13440
BibTeX
@article{Minciuna2024,
author = {Minciuna, Iulia and De Jonge, Jeroen and Den Hoed, Caroline and Maan, Raoel and Polak, Wojciech G and Porte, Robert J and Janssen, Harry L A and Procopet, Bogdan and Darwish Murad, Sarwa},
title = {Antiplatelet Prophylaxis Reduces the Risk of Early Hepatic Artery Thrombosis Following Liver Transplantation in High-Risk Patients},
journal = {Transplant International},
year = {2024},
doi = {10.3389/ti.2024.13440}
}
EUVIMED